References
Gersh BJ, Opie LH. Antithrombotic agents, platelet inhibitors, anticoagulants and fibrinolysis. In: Opie LH, ed. Drugs for the Heart. PhiladeIphia: WBSaunders, 1995: 248-286.
Theroux P. Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: Issues and opportunities. Am Heart J 1998;135:S107-S112.
Hanson SR, Sakarjasson KS. Blood flow and antithrombotic drug effects. Am heart J 1998;135:S132-S142.
Fuster V, Verstraere M. Hemostasis, thrombosis, fibrinolysis and cardiovascular disease. In: Braunwald E, ed. Heart Disease. Philadelphia: WB Saunders, 1997:1809-1882.
Fotts JD, Rowe GG, Rao GHR. Problems with aspirin as antithrombotic agent in coronary artery disease. Lancet 1988;1:937-938.
Cipollone F, Patrignani P, Grew A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109-1116.
Szzeklik A, Musial J, Undas A, et al. Inhibitors of thrombin generation by aspirin is blunted in hypercholesterolemia. Atheroscer Thromb Vasc Biol 1996;16:948-954.
Groteineyer KH, Scharofinski HW, Husstedt IW. Two year follow-up of aspirin responders and aspirin nonresponders: Apilot study including 180 post stroke patients. Thromb Res 1997;71:397-403.
Cryer B, Feldman M. Effects of very low dose daily, long term aspirin therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
Nayen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction. Subroup analysis of the Co-operative New Scandinavian Enalapril Survival Study II(CONSENSUS II). Am J Cardiol 1997;79:115-119.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mittal, S. Aspirin Therapy: Need to Develop Individulized Approach. Cardiovasc Drugs Ther 14, 701–702 (2000). https://doi.org/10.1023/A:1007839620126
Issue Date:
DOI: https://doi.org/10.1023/A:1007839620126